Artificial cornea ideal solution for some

Article

The use of an artificial cornea in patients who have experienced multiple immunologic graft rejections is more likely to result in good-quality vision than is performing another corneal transplant.

The use of an artificial cornea in patients who have experienced multiple immunologic graft rejections is more likely to result in good-quality vision than is performing another corneal transplant, said Michael W. Belin, MD, Albany Medical College, Albany, New York, US.

He provided an update of results of an ongoing international, multicentre study of a proprietary device (Boston Keratoprosthesis; Massachusetts Eye & Ear Infirmary) involving 250 eyes. Dr Belin said that he has been using the device for about five years.

“The major advantage is that, when we look at the survivability of a graft after a second failed graft, the rate of retention of that transplant clarity drops significantly,” he said. “While the success rate on primary grafts is very high, with failure at maybe 10% or less, once we get to two prior grafts, the rejection rate increases to nearly 40%.

“Statistically, patients do much better with a keratoprosthesis than a third, fourth, or fifth transplant, assuming that their cornea is relatively non-vascularized and that they have a reasonable ocular surface,” he said. Visual rehabilitation is faster with the device than with repeated keratoplasty, he added, because astigmatism is not associated with it.

Potential drawbacks of implanting an artificial cornea are similar to those associated with any transplant, Dr Belin said. “Any transplant, particularly repeat transplants, have an increased risk of inducing glaucoma or a pressure problem, and it’s conceivable that the donor rim can melt as a transplant would melt,” he said. “But the prosthesis is very well-tolerated by the eye.”

The multicentre study has demonstrated a graft survival rate of more than 95%, Dr Belin said, “and if we look at the subset of just patients with immunologic graft rejection, not ocular surface disease, the rate increases to about 98%.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.